Sign up USA
Proactive Investors - Run By Investors For Investors

Q BioMed says cancer pain drug will be available later this month

The Strontium Chloride 89 (SR89) injection has been approved by the FDA ..
Q BioMed says cancer pain drug will be available later this month
A cancer cell

Q BioMed Inc (OTCMKTS:QBIO)  said it expects its cancer pain drug to be available later this month (October) and announced the launch of a website for  patients, doctors and caregivers.

The Strontium Chloride 89 (SR89) injection has been approved by the FDA and is a non-opioid injection to relieve bone pain in patients with painful skeletal metastases.

Clinical studies showed the combination of alternating weekly chemohormonal therapies with Strontium-89 demonstrated a prolonged progression-free and overall survival in patients.

The website is at

In the body, Strontium-89 acts in a similar way to calcium and is preferentially taken up in osteoblastic tissue selectively localizing in bone.

Q BioMed shares added 2.13% to US$3.83 each.

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use